Compare Novavax Inc (NVAX) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Target Corporation — how do they compare? Novavax Inc trades at $9.86 (market cap $1.62B), while Target Corporation trades at $158.01 (market cap $73.92B). The key difference: Target Corporation is far larger — about 45.6× Novavax Inc's market cap, and Target Corporation pays a 2.85% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | TGT | |
|---|---|---|
Market Cap | $1.62B | $73.92B |
Sector | Health | Consumer Cyclical |
52-Week High | $11.19 | $169.90 |
52-Week Low | $6.22 | $83.68 |
Enterprise Value | $1.20B | $87.20B |
Dividend Yield | — | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.
The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.
Target (TGT) trades at $162.71, down 1.05% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong profitability with a 26.41% ROE and 4.08% net margin, supported by three consecutive quarterly EPS beats. Revenue remains stable near $107B, while valuation ratios like P/E of 16.88 and P/S of 0.69 suggest reasonable pricing. Recent news highlights CEO Michael Fiddelke's turnaround success, with shares surging over 70% year-to-date.
Outlook is positive with analyst consensus at $166.67 and 47% buy ratings, but risks include competitive retail pressures and margin compression. The dividend yield of approximately 2.85% adds income appeal, though valuation expansion from recent gains warrants caution amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
